NCT05002270View on ClinicalTrials.gov

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

July 31, 2025

Conditions
Advanced Solid TumorNSCLCCRC
Interventions
DRUG

JAB-21822 (KRAS G12C inhibitor)

Administered orally

DRUG

JAB-21822 (KRAS G12C inhibitor)

Administered orally

DRUG

JAB-21822 (KRAS G12C inhibitor)

Administered orally

DRUG

Cetuximab (EGFR inhibitor)

Administered IV

Trial Locations (4)

32224

NOT_YET_RECRUITING

Mayo Clinc, Jacksonville

84112

RECRUITING

University of Utah, Salt Lake City

85054

NOT_YET_RECRUITING

Mayo Clinc, Phoenix

85259

NOT_YET_RECRUITING

Mayo Clinc, Scottsdale

Sponsors
All Listed Sponsors
lead

Jacobio Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | Biotech Hunter | Biotech Hunter